ReviewMolecules (Basel, Switzerland)2021
Emerging Therapeutic Agents for Colorectal Cancer.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epigenetic modulation of autophagy pathway by small molecules in colorectal cancer: a systematic review.Journal of cancer research and clinical oncology · 2024Pooled it
- WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer.EMBO reports · 2025Article
- Article
- Metabolic reprogramming in colorectal cancer: a review of aerobic glycolysis and its therapeutic implications for targeted treatment strategies.Cell death discovery · 2025Review
- Rethinking the rise of early-onset gastrointestinal cancers: a call to action.JNCI cancer spectrum · 2025Article
- Death domain-associated protein (Daxx) impairs colon cancer chemotherapy by inhibiting the cGAS-STING pathway.Oncology research · 2025Article
- Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential.Frontiers in cell and developmental biology · 2024Review
- The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies.Frontiers in pharmacology · 2024Review
- Dual activity of indolin-2-ones containing an arylidene motif: DNA and BSA interaction.RSC advances · 2023Article
- NovelACS pharmacology & translational science · 2023Article
- A review on emerging targeted therapies for the management of metastatic colorectal cancers.Medical oncology (Northwood, London, England) · 2023Review
- Identification and characterization of a first-generation inhibitor of claudin-1 in colon cancer progression and metastasis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.OncoTargets and therapy · 2023Review
- The treatment efficacy of three-layered functional polymer materials as drug carrier for orthotopic colon cancer.Drug delivery · 2022Article
- Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Gold Nanoparticles Synthesized with Common Mullein (Pharmaceutics · 2022Article
- KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFβ signaling in colorectal cancer.Cell death & disease · 2022Article
- Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.International journal of nanomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC's therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.